BEZ235 has been shown to be effective in xenograft models for glioblastoma at higher doses (Liu et al., 2009); however, we were unable to dose at a level required to achieve either inhibition of PI3K and mTOR targets or a survival effect. This evidence concerns the gene MTOR and glioblastoma.